LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Home・Aktien・United Therapeutics Corp

United Therapeutics Corp

Geschlossen

BrancheGesundheitswesen

567.25 -0.12

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

559.78

Max

569.82

Schlüsselkennzahlen
By Trading Economics
Einkommen	-89M 275M
Verkäufe	-8.7M 782M
KGV Branchendurchschnitt	20.882 51.415
EPS	5.82
Gewinnspanne	35.176
Angestellte	1,400
EBITDA	-176M 348M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+14.16% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	29. Juli 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-476M 24B
Vorheriger Eröffnungskurs	567.37
Vorheriger Schlusskurs	567.25

Nachrichtenstimmung

By Acuity

46%

54%

145 / 345 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

292.345 / 309.245 Unterstützung & Widerstand

United Therapeutics Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

United Therapeutics Corp Prognose

Kursziel

By TipRanks

14.16% Vorteil

12-Monats-Prognose

Durchschnitt 649.08 USD 14.16%

Hoch 738 USD

Tief 516 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für United Therapeutics Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

13 ratings

Buy

Halten

Sell

Basierend auf 13 Analysten, die in den letzten 3 Monaten Aktienbewertungen für United Therapeutics Corp – Dist abgegeben haben.

Technischer Score

By Trading Central

292.345 / 309.245Unterstützung & Widerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Stimmung

By Acuity

145 / 345 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.